首页> European journal of haematology> Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

导出 OA

翻译打印收藏纠错

第一作者： Nicola,Gökbuget

第一单位： University Hospital, Goethe University, Frankfurt, Germany.

作者： Nicola,Gökbuget ^[1] ; Hervé,Dombret ^[2] ; Sebastian,Giebel ^[3] ; Monika,Brüggemann ^[4] ; Michael,Doubek ^[5] ; Robin,Foa ^[6] ; Dieter,Hoelzer ^[7] ; Christopher,Kim ^[8] ; Giovanni,Martinelli ^[9] ; Elena,Parovichnikova ^[10] ; Josep,Maria Ribera ^[11] ; Marieke,Schoonen ^[12] ; Catherine,Tuglus ^[13] ; Gerhard,Zugmaier ^[14] ; Renato,Bassan ^[15]

作者单位： University Hospital, Goethe University, Frankfurt, Germany. ^[1] Hôpital Saint-Louis, University Paris Diderot, Paris, France. ^[2] Maria Sklodowska-Curie Institute-Oncology Center, Gliwice, Poland. ^[3] University Hospital Schleswig-Holstein, Kiel, Germany. ^[4] University Hospital and CEITEC Masaryk University, Brno, Czech Republic. ^[5] 'Sapienza' University of Rome, Rome, Italy. ^[6] J.W. Goethe University Hospital, Frankfurt, Germany. ^[7] Center for Observational Research, Amgen Inc, Thousand Oaks, CA, USA. ^[8] Policlinico S Orsola Istituto Seragnoli, Bologna, Italy. ^[9] National Research Center for Hematology, Moscow, Russia. ^[10] ICO-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Barcelona, Spain. ^[11] Centre for Observational Research, Amgen Ltd, Uxbridge, UK. ^[12] Biostatistics, Amgen Inc, Thousand Oaks, CA, USA. ^[13] Clinical Development, Amgen (Europe) GmbH, Munich, Germany. ^[14] UOC Ematologia, Ospedale dell'Angelo, Mestre-Venezia, Italy. ^[15]

关键词 acute lymphoblastic leukaemia clinical trials